ASX, Osteopore strikes Exclusive Distribution Agreement with Zimmer Biomet for its craniofacial products

Highlights

• Osteopore signs an Exclusive Distribution Agreement with Zimmer Pte Ltd, the Singapore-based subsidiary of Zimmer Biomet Holdings, Inc., (Zimmer Biomet) to distribute craniofacial products in Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC) including Australia, and New Zealand.
• Zimmer Biomet is a publicly listed (NYSE and SIX: ZBH) medical technology company, ranked 19th1 in the Top 100 medical device companies globally and #4842 by the Fortune 500 Fortune Rankings.
• The multi-year Agreement comprises 24 countries in the initial stages of distribution.
• The Agreement positions Osteopore to cement its presence in the USD$53.4m (2022) global craniofacial implant market, projected to reach $118.2m by 20323 .